Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  New England Journal of Medicine

• Publication date

  1988-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM198809083191002PMID 3045545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inherited susceptibility to insulin-dependent diabetes is associated with HLA-DR1, while DR5 is protective.

  1988cited by this paper
• Factors associated with early remission of type I diabetes in children treated with cyclosporine.

  1988cited by this paper
• Identification of insulin-dependent diabetes mellitus before the onset of clinical symptoms.

  1988cited by this paper
• Immunosuppressive Therapy in Insulin Dependent Diabetes

  1987cited by this paper
• Maturity-onset diabetes of youth in black Americans.

  1987cited by this paper
• Relation of metabolic control to complications in diabetes mellitus.

  1986cited by this paper
• Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

  1986cited by this paper
• Type I diabetes mellitus. A chronic autoimmune disease.

  1986cited by this paper
• Type I diabetes mellitus. A chronic autoimmune disease.

  1986cited by this paper
• Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

  1986cited by this paper
• Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.

  1985cited by this paper
• Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.

  1985cited by this paper
• Pharmaco-epidemiology--drugs, arthritis, and neoplasms: industry contribution to the data.

  1985cited by this paper
• Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics.

  1985cited by this paper
• Increase in Remission Rate in Newly Diagnosed Type I Diabetic Subjects Treated with Azathioprine

  1985cited by this paper
• Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.

  1985cited by this paper
• Cancer morbidity in rheumatoid arthritis.

  1984cited by this paper
• Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.

  1984cited by this paper
• Cyclosporine-associated chronic nephropathy.

  1984cited by this paper
• Recent experience with 89 pancreas transplants at a single institution

  1984cited by this paper
• BMDP statistical software

  1983cited by this paper
• Insulin antibodies in insulin-dependent diabetics before insulin treatment.

  1983cited by this paper
• The genetic susceptibility to type 1 (insulin-dependent) diabetes: Analysis of the HLA-DR association

  1983cited by this paper
• Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases.

  1982cited by this paper
• Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities.

  1982cited by this paper
• Partial preservation of pancreatic beta-cell function in children with diabetes.

  1981cited by this paper
• The pancreatic islets in diabetes.

  1981cited by this paper
• PARTIAL PRESERVATION OF PANCREATIC β-CELL FUNCTION IN CHILDREN WITH DIABETES

  1981cited by this paper
• Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.

  1980cited by this paper
• Islet Cell and Other Organ-specific Antibodies in U.S. Caucasians and Blacks with Insulin-dependent Diabetes Mellitus

  1980cited by this paper
• Islet-cell antibodies in diabetes mellitus.

  1976cited by this paper
• Letter: Dinitrochlorobenzene sensitisation in congenital syphilis.

  1973cited by this paper
• The association of immune disease and malignant lymphoma.

  1967cited by this paper
• Statistical Principles in Experimental Design

  1963cited by this paper
• Disorders of motility and muscle tone with special reference to the corpus striatum

  year unknowncited by this paper

• Are We Ready With Prevention for Type 1 Diabetes?

  2025cites this paper
• Emerging Immunotherapies for Disease Modification of Type 1 Diabetes

  2025cites this paper
• Targeted Therapies: The Role of Monoclonal Antibodies in Disease Management

  2025cites this paper
• Immunotherapies for prevention and treatment of type 1 diabetes

  2025cites this paper
• A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies

  2025cites this paper
• Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding

  2025cites this paper
• Efficacy of immunosuppression in preserving beta cell function and reducing insulin requirements in Type 1 diabetes mellitus: a comprehensive review

  2025cites this paper
• A capsule-based scaffold incorporating decellularized extracellular matrix and curcumin for islet beta cell therapy in type 1 diabetes mellitus

  2024cites this paper
• Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions

  2024cites this paper
• Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and meta‐regression

  2023cites this paper
• Diagnosis and treatment of allograft rejection in islet transplantation.

  2023cites this paper
• Teplizumab: type 1 diabetes mellitus preventable?

  2023cites this paper
• Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.

  2023cites this paper
• Systemic Metabolism and Mitochondria in the Mechanism of Alzheimer’s Disease: Finding Potential Therapeutic Targets

  2023cites this paper
• Механізм дії та особливості застосування холекальциферолу в дітей та підлітків на етапах розвитку цукрового діабету 1-го типу

  2023cites this paper
• 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes

  2023cites this paper
• Precision medicine in type 1 diabetes

  2022cites this paper
• Leverage biomaterials to modulate immunity for type 1 diabetes

  2022cites this paper
• Glutamic acid decarboxylase immunotherapy for type 1 diabetes

  2022cites this paper
• Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D

  2022cites this paper
• Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

  2021cites this paper
• Features of partial remission in children with type 1 diabetes using the insulin dose-adjusted A1c definition and risk factors associated with nonremission

  2021cites this paper
• 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes

  2021cites this paper
• Guillain-Barré syndrome and myasthenia gravis in the context of autoimmune polyendocrine syndrome type III

  2021cites this paper
• Effect of inflammatory bowel disease treatments on patients with diabetes mellitus

  2021cites this paper
• Type 1 Diabetes in Youth and Technology-Based Advances in Management.

  2020cites this paper
• Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities

  2020cites this paper
• An All-in-One Nanomedicine Consisting of CRISPR-Cas9 and an Autoantigen Peptide for Restoring Specific Immune Tolerance.

  2020cites this paper
• pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression

  2020cites this paper
• Prevention of Autoimmune Disease: The Type 1 Diabetes Paradigm

  2020cites this paper
• Pediatric Diabetes: Review Article

  2019cites this paper
• Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

  2019cites this paper
• Reversal of New Onset Type 1 Diabetes by Oral Salmonella-Based Combination Therapy and Mediated by Regulatory T-Cells in NOD Mice

  2019cites this paper
• Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives

  2018cites this paper
• Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

  2018cites this paper
• Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development

  2017cites this paper
• GAD65: a prospective vaccine for treating Type 1 diabetes?

  2017cites this paper
• Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients.

  2017cites this paper
• 1 Autoimmunity and Immunotherapy of Type 1 Diabetes

  2017cites this paper
• Type 1 diabetes: where are we in 2017?

  2017cites this paper
• Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes

  2017influential citation
• Gastrointestinal Tract and Endocrine System

  2016cites this paper
• Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations

  2016cites this paper
• Progress and challenges for treating Type 1 diabetes.

  2016cites this paper
• Chapter 147 – Autoimmune Endocrine Disorders∗

  2016cites this paper
• Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes

  2016cites this paper
• Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes

  2016cites this paper
• Cohort profile: the German Diabetes Study (GDS)

  2016cites this paper
• The case for an autoimmune aetiology of type 1 diabetes

  2016cites this paper
• Therapies to Preserve β-Cell Function in Type 1 Diabetes

  2016cites this paper
• Chapter 44 – Treatment of Type 1 Diabetes Mellitus in Adults

  2016cites this paper
• Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus

  2016cites this paper
• Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus.

  2016cites this paper
• Revisiting multiple models of progression of β‐cell loss of function in type 1 diabetes: Significance for prevention and cure

  2016cites this paper
• Prevention opportunities of type 1 diabetes in children

  2015cites this paper
• The generation of MHC class I restricted islet antigen specific regulatory T cells for the treatment of type 1 diabetes

  2015cites this paper
• Less Is More: The Detrimental Consequences of Immunosuppressive Therapy in the Treatment of Type-1 Diabetes

  2015cites this paper
• Prevention and Reversal of Type 1 Diabetes d Past Challenges and Future Opportunities

  2015cites this paper
• Prevention and Reversal of Type 1 Diabetes—Past Challenges and Future Opportunities

  2015cites this paper
• Thinking bedside at the bench: the NOD mouse model of T1DM

  2015cites this paper
• 37. Prevention of type 1 diabetes

  2015cites this paper
• Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

  2015cites this paper
• Current Approaches and Future Prospects for the Prevention of β-Cell Destruction in Autoimmune Diabetes

  2015cites this paper
• Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges

  2014cites this paper
• Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development

  2014cites this paper
• Trials in the prevention of type 1 diabetes: current and future.

  2014cites this paper
• The latest pharmacotherapy options for type 1 diabetes

  2014cites this paper
• Prevention of Autoimmune Disease

  2014cites this paper
• Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders

  2014cites this paper
• Immune modulation in humans: implications for type 1 diabetes mellitus

  2014cites this paper
• Islet cell transplantation.

  2014cites this paper
• Targeted immune interventions for type 1 diabetes: not as easy as it looks!

  2014cites this paper
• Glycemic treatment of diabetes mellitus

  2014cites this paper
• Anti-CD3 clinical trials in type 1 diabetes mellitus.

  2013cites this paper
• Syngene Inseltransplantation ins Knochenmark diabetischer Ratten Etablierung der Methode und Erkenntnisse zum Einfluss auf den murinen Glukosestoffwechsel

  2013cites this paper
• Addressing the Challenge of Autoimmunity in the Treatment of Diabetes with Stem Cells

  2013cites this paper
• Inmunoterapia en diabetes mellitus tipo 1. ¿Quo vadis?

  2013cites this paper
• Is type 1 diabetes a food-induced disease?

  2013cites this paper
• Evaluation of Preventive Studies in Type 1 Diabetes Mellitus

  2013cites this paper
• Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial

  2013cites this paper
• Pathophysiology of Immune-Mediated (Type 1) Diabetes Mellitus

  2012cites this paper
• Polymeric nanomaterials for islet targeting and immunotherapeutic delivery.

  2012cites this paper
• Teplizumab for Treatment of Type 1 Diabetes Mellitus

  2012cites this paper
• Prevention Strategies for Type 1 Diabetes Mellitus

  2012cites this paper
• Immunotherapies in diabetes mellitus type 1.

  2012cites this paper
• Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.

  2012cites this paper
• Role of immune system modulation in prevention of type 1 diabetes mellitus

  2012cites this paper
• Novel therapy for type 1 diabetes: Autologous hematopoietic stem cell transplantation

  2012cites this paper
• Immunotherapy for Type 1 diabetes: past and future

  2012cites this paper
• Screening for novel lead compounds increasing insulin expression in medullary thymic epithelial cells.

  2012cites this paper
• Update on global intervention studies in type 1 diabetes.

  2012cites this paper
• Autoimmunity and Immunotherapy of Type 1 Diabetes

  2011cites this paper
• Immunotherapy for Type 1 Diabetes – Preclinical and Clinical Trials

  2011cites this paper
• Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?

  2011cites this paper
• Immunotherapy of Type-1 Diabetes: Immunoprevention and Immunoreversal

  2011cites this paper
• Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes.

  2011cites this paper
• Adiponectin and immune tolerance in type 1 diabetes

  2011cites this paper
• GAD-alum immunotherapy in Type 1 diabetes mellitus.

  2011cites this paper
• Immune and cell therapy in type 1 diabetes: too little too late?

  2011cites this paper
• Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes.

  2011cites this paper